MedicaMetrix Launches Reg A Equity Funding & Public Investor Website


BOSTON, November 4, 2021 / PRNewswire / – MedicaMetrix, Inc. (the “Company”), an innovator in medical device development, has initiated a regulatory A level 2 equity financing (“the Offer”). In addition, the Company has launched an online investor portal containing information and resources for public and accredited investors.

MedicaMetrix is ​​a growing medical device and technology entity with several products in development. The company’s initial product introductions are ProstaMetrixMT, an innovative prostate measurement device, and SureSetMT, a range of IV fixation products. The Company also has other products in the works, and more announcements will be available soon.

“We believe the time has come to invite investors to MedicaMetrix,” said CEO Robert rudelius. “We have seen significant progress in the development of ProstaMetrixMT and SureSetMT and I have no doubts that the company will strengthen its reputation as an emerging force in the medical device industry. “

In recent months, MedicaMetrix has received several authorizations and certifications that will allow the manufacture, distribution and sale of its products both nationally and internationally. The company operates in both United States and India, with clinical trials of ProstaMetrixMT and SureSetMT in progress in several places.

We are delighted to offer public investors the opportunity to invest in the future of our business, ”said CFO Paul Edwards. “We have strategically built MedicaMetrix with a strong management team, high quality operations and, most importantly, innovative products and brands. This offering, along with our investor portal, are the first steps in our journey to build on our solid foundation and deliver a long lifespan. – shareholder value at term. “

MedicaMetrix is ​​offering up to 4,000,000 common voting shares (“Common Shares”), at a price of US $ 5.00 per share. Shares are being offered in accordance with Regulation A of Section 3 (b) of the Securities Act, as amended, for level 2 offers, by management on a “best efforts” basis directly to buyers who meet the requirements set out in Regulation A.

The Company encourages all interested investors to visit for information on how to invest in the Offer, as well as a link to the Offer Circular. The company can also be reached by calling 617.488.9233.

About MedicaMetrix
MedicaMetrix develops innovative medical technologies and device solutions that transform the status quo of healthcare, leading to better medical outcomes, streamlined care and an improved patient experience.

MedicaMetrix is ​​leading the development of a new paradigm that is transforming the diagnosis, treatment and management of prostate health by closing the gap between PSA testing, biopsies and surgery.

MedicaMetrix plans to continue to acquire and develop additional new medical devices with the goal of rapidly bringing them to market by leveraging its production facilities in the United States and India.

Cautions Regarding Forward-Looking Statements
Some of the statements contained in this press release may be forward-looking statements or statements of future expectations based on information currently available. Such statements are naturally subject to risks and uncertainties. Factors such as changes in general economic conditions, future market conditions, unusual catastrophic loss events, changes in capital markets and other circumstances may cause actual events or results to differ materially from those anticipated. by these statements. MedicaMetrix Inc. makes no representations or warranties, express or implied, as to the accuracy, completeness, or updated status of any such statement. Therefore, in no event will MedicaMetrix Inc. and its affiliates be liable to any person for any decision or action taken in conjunction with the information and / or statements contained in this press release or for any related damages.

SOURCE MedicaMetrix, Inc.

Related links

Leave A Reply

Your email address will not be published.